Sales and Marketing

Showing 15 posts of 11528 posts found.

top_10_photo

Top Ten most popular articles on Pharmafile.com this week

October 18, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

It’s time for a rundown of the top 10 articles on PharmaFile this past week. The past seven days saw …
dw-anzcxqaqavhl

2019 saw the FDA approve more generic drugs than ever before

October 18, 2019 Medical Communications, Sales and Marketing FDA, US, generic drugs, pharma

Fiscal year 2019 was a record-breaking one, according to the FDA. The US regulator smashed its previous total for annual …
andrew_dickinson

Gilead appoints Andrew Dickinson as CFO

October 16, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Gilead Sciences have announced that Andrew Dickinson has been appointed as Chief Financial Officer (CFO) effective 1 November. Dickinson currently …
_dsc6281_1

Medical cannabis: Riding the wave

October 16, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kanabo research, medical cannabis, pharma

Following on from our previous piece from Mewburn Ellis on the history of social attitudes towards cannabis, Israel-based Kanabo Research …
shutterstock_273326141

Alexion to acquire Achillion Pharma for $930 million

October 16, 2019 Research and Development, Sales and Marketing Alexion, achillion, merger, pharma

Alexion has revealed it has signed a definitive agreement to acquire Achillion Pharmaceuticals in a deal valued at $930 million, …
eisa0008_web

China approves Eisai’s Fycompa for partial onset epileptic seizures

October 16, 2019 Research and Development, Sales and Marketing China, Eisai, Fycompa, epilepsy, pharma

Tokyo-headquartered firm Eisai has announced that its antiepileptic drug (AED) Fycompa (perampanel) has received approval from China’s National Medical Products …

FDA approves first and only transdermal patch for schizophrenia

October 16, 2019 Research and Development, Sales and Marketing FDA, Noven Pharma, Secuado, US, pharma, schizophrenia

Hisamitsu Pharmaceutical subsidiary Noven Pharmaceuticals has revealed the FDA approval of Secuado (asenapine) in adult schizophrenia patients, making it the …

Lilly’s Reyvow becomes first FDA-approved 5-HT1F receptor agonist for acute migraine

October 15, 2019 Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Reyvow, US, migraine, pharma

Eli Lilly has announced that the FDA has given the green light to Reyvow (lasmiditan) in the acute treatment of …
janssen_latest_logo_on_sign_closer

FDA approves Janssen’s Xarelto for blood clot prevention

October 15, 2019 Manufacturing and Production, Sales and Marketing FDA, Janssen, US, Xarelto, pharma, thromboembolism

Janssen’s Xarelto (rivaroxaban) has secured FDA approval for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalised acutely …
_dsc6538

Medical cannabis: On to greener pastures?

October 14, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing medical cannabis, medicinal cannabis, pharma

In the first of three articles on the topic, Callum McGuinn, Associate and European Patent Attorney at Mewburn Ellis, explores …

Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis

October 14, 2019 Research and Development, Sales and Marketing Pfizer, abrocitinib, atopic dermatitis, pharma

Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and …
index_ph001

Daiichi Sankyo show low CV events and bleeding in NVAF patients on Lixiana

October 14, 2019 Sales and Marketing

Daiichi Sankyo have announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients treated with …
shionogi

Shionogi reports positive results for cefiderocol in pneumonia

October 14, 2019 Sales and Marketing

Shionogi has reported positive data from a trial of its investigational antibiotic cefiderocol which is already under regulatory review in …
roche__tree

Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris

October 14, 2019 Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma

Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …

Three focus areas to accelerate breakthrough drugs to market

October 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing veeva

The number of clinical trials taking place each year continues to rise. In fact, in 2018, the FDA approved a …
The Gateway to Local Adoption Series

Latest content